Cargando…

Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy

Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver dam...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiri Aghbash, Parisa, Ebrahimzadeh Leylabadlo, Hamed, Fathi, Hamidreza, Bahmani, Mohaddeseh, Chegini, Rojin, Bannazadeh Baghi, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754839/
https://www.ncbi.nlm.nih.gov/pubmed/36531832
http://dx.doi.org/10.1155/2022/4291758
_version_ 1784851289616678912
author Shiri Aghbash, Parisa
Ebrahimzadeh Leylabadlo, Hamed
Fathi, Hamidreza
Bahmani, Mohaddeseh
Chegini, Rojin
Bannazadeh Baghi, Hossein
author_facet Shiri Aghbash, Parisa
Ebrahimzadeh Leylabadlo, Hamed
Fathi, Hamidreza
Bahmani, Mohaddeseh
Chegini, Rojin
Bannazadeh Baghi, Hossein
author_sort Shiri Aghbash, Parisa
collection PubMed
description Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease.
format Online
Article
Text
id pubmed-9754839
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-97548392022-12-16 Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy Shiri Aghbash, Parisa Ebrahimzadeh Leylabadlo, Hamed Fathi, Hamidreza Bahmani, Mohaddeseh Chegini, Rojin Bannazadeh Baghi, Hossein Can J Gastroenterol Hepatol Review Article Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease. Hindawi 2022-12-08 /pmc/articles/PMC9754839/ /pubmed/36531832 http://dx.doi.org/10.1155/2022/4291758 Text en Copyright © 2022 Parisa Shiri Aghbash et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Shiri Aghbash, Parisa
Ebrahimzadeh Leylabadlo, Hamed
Fathi, Hamidreza
Bahmani, Mohaddeseh
Chegini, Rojin
Bannazadeh Baghi, Hossein
Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy
title Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy
title_full Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy
title_fullStr Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy
title_full_unstemmed Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy
title_short Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy
title_sort hepatic disorders and covid-19: from pathophysiology to treatment strategy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754839/
https://www.ncbi.nlm.nih.gov/pubmed/36531832
http://dx.doi.org/10.1155/2022/4291758
work_keys_str_mv AT shiriaghbashparisa hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy
AT ebrahimzadehleylabadlohamed hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy
AT fathihamidreza hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy
AT bahmanimohaddeseh hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy
AT cheginirojin hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy
AT bannazadehbaghihossein hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy